Financial Reports
Our financial reports are only available in Swedish.
AcuCort publishes the Interim Report for the second quarter 2022 (in Swedish)
Message from the CEO
“It is gratifying that the company’s first approved drug, previously under the name ISICORT in Sweden, is now approved throughout Scandinavia under one and the same name – Zeqmelit™.”
Jonas Jönmark, CEO, AcuCort AB
November 11, 2022
We make good drugs better
AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.